Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
This is the gene therapy story nobody wanted but everybody expected. Sangamo Therapeutics, which pioneered zinc finger nuclease technology and built one of the earliest
Pfizer paid $43 billion for Seagen in 2023 to become an ADC powerhouse. The deal brought in Padcev (bladder cancer), Adcetris (lymphoma), and Tivdak (cervical
AbbVie knows immunology better than almost anyone. Humira made the company more than $200 billion before it went off patent. Skyrizi and Rinvoq are growing
Last Wednesday, Biogen executives told Fierce Biotech the company was becoming “the new Biogen” through external partnerships and acquisitions. Five days later, the company wrote
Moderna’s long-term commercial thesis has always been bigger than COVID. If the mRNA platform can make better flu vaccines, respiratory combination shots, and pandemic-ready constructs,
PwC’s midyear outlook has now put the official stamp on what we have tracked since January: 2026 is a historic dealmaking year. The firm reported
Cisplatin was first approved in 1978. Carboplatin followed in 1989. Nearly fifty years later, these drugs remain standard of care across virtually every solid tumor
Novartis is making the largest single-modality bet in pharmaceutical history on molecular glues. The company signed its second collaboration with Orionis Biosciences for up to
When Lilly acquired Ajax Therapeutics for up to $2.3 billion in April, the deal was a bet on a Phase 1 asset with no clinical
The outsourced pharmaceutical manufacturing sector is booming in aggregate, but the benefits are not evenly distributed. The Pharma Letter published an analysis showing that scale
